SCHEMBL14239784

SCHEMBL14239784

CCCCCCCC/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCN(C)C

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.63
MGLL Q99685 1/20 0.50
EPHX2 P34913 3/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
THRB P10828 1/20 0.49
CNR1 P21554 1/20 0.49
DGKA P23743 2/20 0.49
FAAH O00519 2/20 0.47
LPAR1 Q92633 4/20 0.46
CES2 O00748 1/20 0.46
ENPP2 Q13822 1/20 0.46
LPAR4 Q99677 1/20 0.46
LPAR5 Q9H1C0 1/20 0.46
LPAR2 Q9HBW0 1/20 0.46
LPAR3 Q9UBY5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17586403 0.97 DNM1 (0.63) DNM1MGLLEPHX2ALDH1A1MAPT
SCHEMBL18350944 0.96 DNM1 (0.59) DNM1MGLLALDH1A1MAPTTHRB
SCHEMBL21026912 0.94 DNM1 (0.59) DNM1MGLLEPHX2ALDH1A1MAPT
SCHEMBL12179617 0.94 DNM1 (0.65) DNM1MGLLEPHX2ALDH1A1MAPT
SCHEMBL22269543 0.93 DNM1 (0.55) DNM1MGLLALDH1A1MAPTTHRB
SCHEMBL21026929 0.93 DNM1 (0.55) DNM1MGLLEPHX2ALDH1A1MAPT
SCHEMBL18350892 0.93 DNM1 (0.58) DNM1MGLLEPHX2ALDH1A1MAPT
SCHEMBL17877550 0.93 DNM1 (0.58) DNM1MGLLALDH1A1MAPTTHRB
SCHEMBL15027026 0.93 DNM1 (0.57) DNM1MGLLEPHX2ALDH1A1MAPT
SCHEMBL17613217 0.92 DNM1 (0.57) DNM1MGLLEPHX2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858974-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2022-07-20 EP disclosed
EP-3489220-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-11-10 EP disclosed
EP-3489220-B1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-08-18 EP disclosed
US-11084779-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2021-08-10 US disclosed
US-10961181-B2 2021-03-30 US disclosed
EP-3127915-B1 RBP-DERIVED TARGETING MOLECULE AND UTILIZATION THEREOF NITTO DENKO CORP (JP) 2020-08-26 EP disclosed
US-20200199064-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2020-06-25 US disclosed
US-20200085957-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2020-03-19 US disclosed
US-10441659-B2 Lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2019-10-15 US disclosed
US-20190275158-A1 SKIN FIBROSIS TREATMENT AGENT NITTO DENKO CORP (JP) 2019-09-12 US disclosed
US-9242001-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2016-01-26 US disclosed
US-9242001-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2016-01-26 US disclosed
US-9011903-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2015-04-21 US disclosed
US-9011903-B2 Cationic lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2015-04-21 US disclosed
US-20140294934-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2014-10-02 US disclosed
US-20140294934-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2014-10-02 US disclosed
WO-2012170952-A9 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2013-02-21 WO disclosed
US-20130022665-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2013-01-24 US disclosed
US-20130022665-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2013-01-24 US disclosed
WO-2012170952-A2 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2012-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022665-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS SGMS1, SGMS2, S1PR3 DNM1 714/4885MGLL 181/4885EPHX2 818/4885
US-20200085957-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS LIPA, SGMS2, SGMS1 DNM1 235/4885MGLL 84/4885EPHX2 1794/4885
US-20200199064-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS SGMS1, SGMS2, CERT1 DNM1 826/4885MGLL 255/4885EPHX2 1271/4885
US-10441659-B2 Lipids for therapeutic agent delivery formulations LIPA, SGMS2, SGMS1 DNM1 235/4885MGLL 84/4885EPHX2 1794/4885
US-20190275158-A1 SKIN FIBROSIS TREATMENT AGENT COL1A1, COLGALT1, COL14A1 DNM1 4615/4885MGLL 3067/4885EPHX2 445/4885
US-20140294934-A1 CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS SGMS1, SGMS2, S1PR3 DNM1 665/4885MGLL 181/4885EPHX2 737/4885
US-10961181-B2 DEGS1, SGMS1, C5 DNM1 2316/4885MGLL 1111/4885EPHX2 473/4885
US-11084779-B2 Cationic lipids for therapeutic agent delivery formulations SGMS1, SGMS2, CERT1 DNM1 826/4885MGLL 255/4885EPHX2 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.